Shire, which operates out of the U.S. but has its domicile in Ireland for tax reasons, will build its first manufacturing facility in its adopted country.

Valeant has called in investment banks to help it decide which products it might quickly turn into cash if it decides to sell some to pay down its $30 billion…

Allergan CEO Brent Saunders has said tax rule changes appeared unfairly targeted toward his company's proposed merger with Pfizer. Not so, Treasury head…

Orexigen lost its Contrave marketing partner Takeda last month. Now, the drugmaker has terminated its second try at an FDA-mandated heart safety study, putting…

Merck and Bristol-Myers, locked in head-to-head competition in lung cancer and melanoma, step closer to new indications where they won't lock horns.

The annual report on how much the U.S. pays for meds is out--and it will likely serve to further anger those who believe pharma is hiking its prices.

Regulators signed off on more than 700 generic drugs last year--the highest figure to date, according to the FDA’s first generics annual report, which the…

Many of you saw the new FierceBiotech website launch earlier this week and now I am pleased to bring you the newly redesigned FiercePharma.  Our new website …

Merck wants its new weekly diabetes treatment, Marizev, to build on the success of its blockbuster DPP-4 inhibitor Januvia. But at least when it comes to…

There is more uncertainty on the horizon for investors in Horizon. Last month, it was the disclosure of a Department of Justice (DOJ) probe into pricing. Today…